# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

### **Equality impact assessment – Guidance development**

# The VeriQ system for assessing graft flow during coronary artery bypass graft surgery

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No potential equality issues were identified during the scoping process.

2. Have any other potential equality issues been highlighted in the manufacturer's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these?

No potential equality issues were highlighted in the manufacturer's submission or in patient organisation questionnaires.

3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these?

No other potential equality issues were highlighted by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No specific groups have been identified in the preliminary recommendations.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

Not applicable

**Approved by Associate Director: Mark Campbell** 

Date: 1 September 2011

### Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No potential equality issues were highlighted during the consultation

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

4. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

Not applicable

**Approved by Programme Director: Mirella Marlow** 

Date: 08 November 2011